CS MEDICA Stock Now Also Traded on XETRA
|
EQS-News: CS MEDICA A/S
/ Key word(s): Capital Markets Day
The shares of CS MEDICA A/S (ISIN DK0061668225) have been listed on the Frankfurt Stock Exchange since March 2, 2023. The company, a MedTech pioneer in the development of medical devices that benefit from bioactive CBD, has mandated the private bank Hauck Aufhäuser Lampe to include the company's shares in Deutsche Börse AG's trading venue XETRA and ensure continuous trading.
As of today, the 12,322,635 registered shares of the company can now also be traded via the electronic trading system XETRA. In the electronic trading system XETRA, Designated Sponsors provide additional liquidity by committing to place binding bid and ask sizes (so-called quotes) in the order book for the securities they support during continuous trading and auctions. The private bank Hauck Aufhäuser Lampe ensures higher liquidity in the stock in this way. High-quality criteria (minimum requirements) are imposed on Designated Sponsors by Deutsche Börse AG for liquidity provision. Thereby, the private bank Hauck Aufhäuser Lampe has achieved the highest rating from Deutsche Börse ('AA') for years. "By including our shares in the XETRA trading platform, we offer both existing and future shareholders an additional trading opportunity," says Lone Henriksen, CEO of CS MEDICA A/S. "By committing to a Designated Sponsor, we aim to further increase the liquidity of CS MEDICA stock and strengthen the free float. This should minimize the spread between bid and ask prices." CS MEDICA Group, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally. CANNORDIC A/S, a subsidiary of CS MEDICA Group, is a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation, science, technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The company ensures robust research, development, manufacturing, compliance, data insights, and commercialization processes. The group's shares are traded on the stock exchanges and trading platforms in Frankfurt, Munich, Stuttgart, and XETRA, as well as on the Spotlight Stock Market in Stockholm under ISIN DK0061668225.
01.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | CS MEDICA A/S |
| Indiakaj 10,2 | |
| 2100 Copenhagen | |
| Denmark | |
| Phone: | +45 70707337 |
| E-mail: | info@cs-medica.com |
| Internet: | https://www.cs-medica.com |
| ISIN: | DK0061668225 |
| WKN: | A3CYEQ |
| Listed: | Regulated Unofficial Market in Frankfurt, Munich, Stuttgart |
| EQS News ID: | 1936153 |
| End of News | EQS News Service |
|
|
1936153 01.07.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.